['epidermolysis bullosa']
['sd-101-6.0 cream', 'placebo (sd-101-0.0) cream']

        Inclusion Criteria:

          -  Informed Consent form signed by the participant or participant's legal representative;
             if the participant was under the age of 18 but capable of providing assent, signed
             assent from the participant.

          -  Participant (or caretaker) must have been willing to comply with all protocol
             requirements.

          -  Diagnosis of Simplex, Recessive Dystrophic, or Junctional non-Herlitz EB.

          -  Participant must have had 1 target wound (size 10 to 50 cm^2) at study entry.

          -  Participants 1 month and older.

          -  Target wound must have been present for at least 21 days.

        Exclusion Criteria:

          -  Participants who did not meet the entry criteria outlined above.

          -  Selected target wound did not have clinical evidence of local infection.

          -  Use of any investigational drug within the 30 days before enrollment.

          -  Use of immunotherapy or cytotoxic chemotherapy within the 60 days before enrollment.

          -  Use of systemic or topical steroidal therapy within the 30 days before enrollment.
             (Inhaled steroids and ophthalmic drops containing steroids were allowed).

          -  Use of systemic antibiotics within the 7 days before enrollment.

          -  Current or former malignancy.

          -  Arterial or venous disorder resulting in ulcerated lesions.

          -  Pregnancy or breastfeeding during the study. (A urine pregnancy test was performed at
             screening and every 30 days until the final visit for female participants of
             childbearing potential).

          -  Females of childbearing potential who were not abstinent and not practicing a
             medically acceptable method of contraception.
      